Analysts predict that Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Rating) will announce earnings per share of ($0.65) for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Tarsus Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($0.96). Tarsus Pharmaceuticals reported earnings per share of $0.29 in the same quarter last year, which suggests a negative year over year growth rate of 324.1%. The company is scheduled to issue its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that Tarsus Pharmaceuticals will report full year earnings of ($3.37) per share for the current financial year, with EPS estimates ranging from ($4.26) to ($2.40). For the next fiscal year, analysts forecast that the business will report earnings of ($4.96) per share, with EPS estimates ranging from ($5.28) to ($4.32). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating) last announced its earnings results on Monday, March 14th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 25.85% and a negative net margin of 184.14%. The business had revenue of $0.34 million for the quarter, compared to analysts’ expectations of $7.11 million.
In other news, Director Michael Ackermann bought 100,000 shares of the stock in a transaction dated Thursday, May 5th. The shares were bought at an average cost of $13.50 per share, with a total value of $1,350,000.00. Following the completion of the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at $1,350,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Vivo Capital Ix, Llc sold 41,800 shares of the company’s stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $15.19, for a total value of $634,942.00. Following the transaction, the insider now directly owns 2,945,531 shares in the company, valued at $44,742,615.89. The disclosure for this sale can be found here. 33.08% of the stock is currently owned by insiders.
Large investors have recently modified their holdings of the company. BlackRock Inc. grew its holdings in Tarsus Pharmaceuticals by 0.7% during the third quarter. BlackRock Inc. now owns 441,620 shares of the company’s stock worth $9,519,000 after buying an additional 3,264 shares in the last quarter. Morgan Stanley bought a new stake in Tarsus Pharmaceuticals during the second quarter worth $241,000. Bank of America Corp DE grew its holdings in Tarsus Pharmaceuticals by 84.8% during the fourth quarter. Bank of America Corp DE now owns 10,662 shares of the company’s stock worth $240,000 after buying an additional 4,891 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in Tarsus Pharmaceuticals during the fourth quarter worth $202,000. Finally, UBS Group AG grew its holdings in Tarsus Pharmaceuticals by 37.0% during the first quarter. UBS Group AG now owns 4,226 shares of the company’s stock worth $71,000 after buying an additional 1,142 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors.
TARS stock traded up $0.50 during trading on Tuesday, hitting $14.49. The company had a trading volume of 195,740 shares, compared to its average volume of 109,902. The business has a 50-day moving average of $16.27 and a 200-day moving average of $19.86. Tarsus Pharmaceuticals has a one year low of $10.80 and a one year high of $39.08. The stock has a market cap of $300.33 million, a PE ratio of -6.68 and a beta of 1.45. The company has a current ratio of 14.18, a quick ratio of 14.18 and a debt-to-equity ratio of 0.13.
Tarsus Pharmaceuticals Company Profile (Get Rating)
Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
- Get a free copy of the StockNews.com research report on Tarsus Pharmaceuticals (TARS)
- Zoom Video Communications Is Primed To Launch Higher
- Institutions Buy The Dip In Petco Health and Wellness Company
- Veeva Systems: Increasing NDR and Other Wins
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Autozone Edges Past Advanced Auto Parts In Q1 2022
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.